EP2044950A3 - Attenuated VIF DNA immunization cassettes for genetic vaccines - Google Patents

Attenuated VIF DNA immunization cassettes for genetic vaccines Download PDF

Info

Publication number
EP2044950A3
EP2044950A3 EP08075892A EP08075892A EP2044950A3 EP 2044950 A3 EP2044950 A3 EP 2044950A3 EP 08075892 A EP08075892 A EP 08075892A EP 08075892 A EP08075892 A EP 08075892A EP 2044950 A3 EP2044950 A3 EP 2044950A3
Authority
EP
European Patent Office
Prior art keywords
cassettes
dna immunization
genetic vaccines
attenuated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08075892A
Other languages
German (de)
French (fr)
Other versions
EP2044950B1 (en
EP2044950A2 (en
Inventor
Velpandi Ayyavoo
Thanadavarayan Nagashunmugam
David B. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP2044950A2 publication Critical patent/EP2044950A2/en
Publication of EP2044950A3 publication Critical patent/EP2044950A3/en
Application granted granted Critical
Publication of EP2044950B1 publication Critical patent/EP2044950B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
EP08075892A 1997-09-18 1998-09-18 Attenuated VIF DNA immunization cassettes for genetic vaccines Expired - Lifetime EP2044950B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5928397P 1997-09-18 1997-09-18
US6017297P 1997-09-26 1997-09-26
EP98946105A EP1015009A4 (en) 1997-09-18 1998-09-18 Attenuated vif dna immunization cassettes for genetic vaccines

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP98946105.8 Division 1998-09-18
EP98946105A Division EP1015009A4 (en) 1997-09-18 1998-09-18 Attenuated vif dna immunization cassettes for genetic vaccines

Publications (3)

Publication Number Publication Date
EP2044950A2 EP2044950A2 (en) 2009-04-08
EP2044950A3 true EP2044950A3 (en) 2009-07-01
EP2044950B1 EP2044950B1 (en) 2012-06-27

Family

ID=26738576

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98946105A Withdrawn EP1015009A4 (en) 1997-09-18 1998-09-18 Attenuated vif dna immunization cassettes for genetic vaccines
EP08075892A Expired - Lifetime EP2044950B1 (en) 1997-09-18 1998-09-18 Attenuated VIF DNA immunization cassettes for genetic vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP98946105A Withdrawn EP1015009A4 (en) 1997-09-18 1998-09-18 Attenuated vif dna immunization cassettes for genetic vaccines

Country Status (9)

Country Link
US (2) US7151172B1 (en)
EP (2) EP1015009A4 (en)
JP (2) JP4418101B2 (en)
AU (1) AU752725B2 (en)
CA (1) CA2304125A1 (en)
DK (1) DK2044950T3 (en)
ES (1) ES2389519T3 (en)
PT (1) PT2044950E (en)
WO (1) WO1999013896A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170092A1 (en) 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
KR102334637B1 (en) 2006-07-28 2021-12-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Improved vaccines and methods for using the same
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (en) 2010-10-01 2019-09-24 Moderna Therapeutics Inc manipulated nucleic acids and methods of use thereof.
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005851A1 (en) * 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP3881689B2 (en) 1992-03-11 2007-02-14 パウダージェクト ヴァクシンズ，インコーポレイテッド Genetic vaccine for immunodeficiency virus
WO1993023552A1 (en) 1992-05-21 1993-11-25 Government Of The United States As Represented By Secretary Department Of Health And Human Services Targeting gene expression to living tissue using jet injection
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005851A1 (en) * 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
KIM J J ET AL: "Development of a multicomponent candidate vaccine for HIV-1", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 879 - 883, XP004075675, ISSN: 0264-410X *
MILLER R H ET AL: "HIV ACCESSORY PROTEINS AS THERAPEUTIC TARGETS VIRAL REGULATORY PROTEINS REPRESENT NEW TARGETS FOR THERAPEUTIC ANDPREVENTION STRATEGIES AGAINST HIV", NATURE MEDICINE,NATURE PUBLISHING, CO,US, vol. 3, no. 4, April 1997 (1997-04-01), pages 389 - 394, XP001005617, ISSN: 1078-8956 *
NL. MICHAEL ET AL.,: "Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus", J. VIROL., vol. 69, no. 7, July 1995 (1995-07-01), pages 4228 - 4236, XP002171662 *
P. SOVA ET AL.,: "Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo", J. VIROL, vol. 69, no. 4, April 1995 (1995-04-01), pages 2557 - 2564, XP002171663 *
T. NAGASHUNMUGAM AND HM FRIEDMAN: "Cell-free HIV-1Zr6 vif mutants are defective in binding to peripheral blood mononuclear cells and in internalization", DNA CELL BIOL, vol. 15, no. 5, May 1996 (1996-05-01), pages 353 - 361, XP000999264 *
U. WIELAND ET AL.,: "In vivo genetic variability of the HIV-1 vif gene", VIROLOGY, vol. 203, no. 1, 15 August 1994 (1994-08-15), pages 43 - 51, XP000999254 *
UGEN K E ET AL: "DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 19, 1 November 1998 (1998-11-01), pages 1818 - 1821, XP004139012, ISSN: 0264-410X *
V. AYYAVOO ET AL.,: "Development of genetic vaccines for pathogenic genes : construction of attenuated vif DNA immunization cassettes", AIDS, vol. 11, no. 12, October 1997 (1997-10-01), pages 1433 - 1444, XP001005662 *
WIELAND U ET AL: "ANTIGENIC DOMAINS OF THE HIV-1 VIF PROTEIN AS RECOGNIZED BY HUMAN SERA AND MURINE MONOCLONAL ANTIBODIES", AIDS RESEARCH AND HUMAN RETROVIRUSES,NEW YORK, NY,US, vol. 7, no. 11, November 1991 (1991-11-01), pages 861 - 867, XP001005425, ISSN: 0889-2229 *

Also Published As

Publication number Publication date
CA2304125A1 (en) 1999-03-25
US8183352B2 (en) 2012-05-22
JP4749481B2 (en) 2011-08-17
EP1015009A4 (en) 2001-11-07
AU752725B2 (en) 2002-09-26
PT2044950E (en) 2012-09-18
JP2001516566A (en) 2001-10-02
EP1015009A1 (en) 2000-07-05
EP2044950B1 (en) 2012-06-27
ES2389519T3 (en) 2012-10-26
JP2010001290A (en) 2010-01-07
US20070106062A1 (en) 2007-05-10
EP2044950A2 (en) 2009-04-08
AU9319098A (en) 1999-04-05
DK2044950T3 (en) 2012-09-17
JP4418101B2 (en) 2010-02-17
US7151172B1 (en) 2006-12-19
WO1999013896A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
EP2044950A3 (en) Attenuated VIF DNA immunization cassettes for genetic vaccines
CA2190473A1 (en) Recombinant papilloma virus l1
ZA200201043B (en) Novel B7-4 molecules and uses thereof.
EP1054683A4 (en) Modified heat shock protein-antigenic peptide complex
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
AU3406595A (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
KR970705408A (en) Haemophilus adhesion and penetration proteins (HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS)
DK0929677T3 (en) Recombinant method for producing a complete malaria antigen GP190 / MSP1
WO2002016591A3 (en) Human transporter family members and uses thereof
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
WO2002026803A3 (en) 22108 and 47916, novel human thioredoxin family members and uses thereof
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002085287A3 (en) Minimal adenoviral vectors for immunization
DE3877136D1 (en) RECOMBINANT HISTIDINE PROTEIN OF PLASMODIUM FALCIPARUM, ITS PRODUCTION AND USE.
WO2001064905A3 (en) 2504, 15977, and 14760, novel protein kinase family members and uses therefor
WO2002016568A3 (en) 46863, a human methyltransferase and uses thereof
WO2002020801A3 (en) 26199, 33530, 33949, 47148, 50226, and 58764, human transferase family members and uses therefor
WO2002018439A3 (en) 52991, a human transporter protein and uses therefor
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2003035840A3 (en) 69583 and 85924, novel human protein kinase family members and uses therefor
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
WO2002051992A3 (en) 21163, a novel human prolyl oligopeptidase and uses therefor
WO2002010401A3 (en) 18431 and 32374, human protein kinase family members and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1015009

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17P Request for examination filed

Effective date: 20091221

17Q First examination report despatched

Effective date: 20100122

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1015009

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 563769

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69842782

Country of ref document: DE

Effective date: 20120830

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20120912

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2389519

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20121026

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120401939

Country of ref document: GR

Effective date: 20120920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130328

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69842782

Country of ref document: DE

Effective date: 20130328

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20130903

Year of fee payment: 16

Ref country code: NL

Payment date: 20130926

Year of fee payment: 16

Ref country code: PT

Payment date: 20130318

Year of fee payment: 16

Ref country code: DK

Payment date: 20130925

Year of fee payment: 16

Ref country code: SE

Payment date: 20130927

Year of fee payment: 16

Ref country code: ES

Payment date: 20130926

Year of fee payment: 16

Ref country code: DE

Payment date: 20130927

Year of fee payment: 16

Ref country code: FI

Payment date: 20130927

Year of fee payment: 16

Ref country code: IE

Payment date: 20130925

Year of fee payment: 16

Ref country code: GR

Payment date: 20130926

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20130927

Year of fee payment: 16

Ref country code: FR

Payment date: 20130919

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130925

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20130927

Year of fee payment: 16

Ref country code: CH

Payment date: 20130927

Year of fee payment: 16

Ref country code: LU

Payment date: 20131008

Year of fee payment: 16

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20150318

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69842782

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 563769

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140918

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20120401939

Country of ref document: GR

Effective date: 20150403

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140919

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69842782

Country of ref document: DE

Effective date: 20150401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150401

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150401

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140918

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150403

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20151028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140919